Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition
Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.
Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.
Check out news from BioMEMS Diagnostics, Rx Redefined, Ferrum Health and Avanlee Care.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Process improvement and advanced technology can also help relieve the staffing burden that medical laboratories are facing.
Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.
Targeted drugs and immunotherapies are among the advances that contribute to declines in incidence and deaths from non-small cell lung cancer, according to the Annual Report to the Nation on the Status of Cancer. But the trends are on the rise for some other cancers and racial disparities persist, highlighting the need to better understand these differences.
The breast cancer solution will help determine which patients would benefit from targeted therapies and which patients could avoid chemotherapy. Meanwhile, the colorectal solution will be able to match patients with the most effective treatment sooner.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Beyond preparedness policies, we need to think forward to policies that rapidly identify the spread of zoonotic disease to prevent or minimize the impact.
Advanced technologies, such as AI-guided robotics and automation, offer a potential solution to the provider shortage by freeing healthcare professionals from repetitive and time-consuming tasks and allow clinicians to focus on tasks that require a specialized touch.
Check out new developments from BioMEMS Diagnostics, Neuroflow, Druglike, Health Note, and Rhinostics.
Check out news from Equiva, Canvas Medical, Particle Health, Fold Health, and Nucleus Genomics.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
With the information contained in a simple 30-second voice sample, providers can help patients get ahead of future health issues and prescribe or adjust treatment plans as needed.
MedArrive providers will use Spect’s artificial intelligence-enabled telemedicine platform to screen patients at home for eye diseases such as diabetic retinopathy, glaucoma and age-related macular degeneration.
The point of care diagnostics and testing market has climbed dramatically with the rise of the Covid-19 public health crisis. We're seeking applications for diagnostics startups who would like to take part in INVEST Pitch Perfect Diagnostics 2.0 track at the conference, scheduled to take place March 28-30 in Chicago.
It turns out that the laws governing traditional Medicare don’t provide for coverage of self-administered diagnostic tests. Medicare patients are left to seek free tests other ways, including through the administration’s new website, covidtests.gov, and at community centers.
The transaction also brought a $200 million investment for Sema4 from life science investors including Pfizer, which can help the combined company's goal of translating insights from genomics data and analytics into making precision medicine a standard of care.